ML models co-optimize antibody affinity and specificity in novel mutational space
Source check: Needs source check. Not independent scientific confirmation.
Finding: For emibetuzumab, CDR mutant libraries were sorted for affinity and non-specific binding and deep sequenced; ML models trained on binary labels predicted continuous metrics and generalized to novel mutations, exposing trade-offs between the two properties. Abstract-level review only; truncated reading.
Technology: Machine learning models on deep-mutational sort data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Models predicted binding properties for unseen variants to select improved antibodies.
- Test and result
- Predictions compared with measured binding on held-out variants.
- Limitation / still unknown
- Single antibody; clinical developability not assessed; full text not read.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://europepmc.org/search?query=DOI%3A10.1038/s41467-022-31457-3
Needs source check · editorial details
The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.